secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-10-09T20:30:27+00:00
Accession:  0001493152-26-046548
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

bioAffinity Technologies closes $4M registered direct offering and concurrent private placement
--------------------------------------------------------------------------------

- Entered Oct 8, 2026 securities purchase agreement for 116,545 shares at $6.122 and pre-funded warrants for 536,836 shares at $6.115.
- Concurrent private placement issued warrants for up to 980,072 shares at $6.122, exercisable after stockholder approval and expiring five years later.
- Gross proceeds approximately $4 million; closing occurred Oct 9, 2026; net proceeds for working capital and CyPath Lung sales support.
- WallachBeth Capital LLC is sole placement agent; cash fee 7.5% of gross proceeds, $70,000 expenses, and warrants for 19,602 shares at $6.122.
- Company suspended ATM prospectus supplement dated May 27, 2025 under sales agreement with Placement Agent; sales agreement remains in effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226046548/0001493152-26-046548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226046548/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-046548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer